Antibodies

30 Dec 2020 Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
29 Dec 2020 Celltrion Submits Application for Conditional Marketing Authorisation of Its COVID-19 Treatment Candidate CT-P59 to the Korean MFDS
28 Dec 2020 Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
23 Dec 2020 Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
23 Dec 2020 Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome
23 Dec 2020 OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011
23 Dec 2020 Halozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Canc
23 Dec 2020 Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum™ and Has Requested Priority Review
22 Dec 2020 Ridgeback Biotherapeutics LP Announces the Approval of EbangaTM for Ebola
22 Dec 2020 Update on SOURCE Phase III trial for tezepelumab in patients with severe, oral corticosteroid-dependent asthma
22 Dec 2020 Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of Blindness
18 Dec 2020 New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
18 Dec 2020 MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
18 Dec 2020 miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
18 Dec 2020 Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
18 Dec 2020 Ology Bioservices Enters Phase 1 Clinical Trial for Anti-COVID-19 Monoclonal Antibodies
18 Dec 2020 MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
18 Dec 2020 Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
18 Dec 2020 FDA approves GSK’s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
18 Dec 2020 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Esophageal and Gastroesophageal Junction Cancer
18 Dec 2020 FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
18 Dec 2020 Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program
17 Dec 2020 Regeneron Provides Update on Odronextamab Clinical Trials in B-cell Non-Hodgkin Lymphomas
17 Dec 2020 Imfinzi recommended for approval in the EU by CHMP for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
16 Dec 2020 Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top